WHAT IS NEOADJUVANT CHEMOTHERAPY?

Neoadjuvant chemotherapy is systemic drug treatment administered before radical cystectomy in appropriately selected patients with Muscle-Invasive Bladder Cancer (MIBC). Its primary goals are to eliminate microscopic cancer cells that may have spread beyond the bladder, reduce tumor burden, improve surgical outcomes, and increase long-term survival. According to the 2026 European Association of Urology (EAU) Guidelines, cisplatin-based neoadjuvant chemotherapy is the standard of care for eligible patients with muscle-invasive bladder cancer.

TABLE OF CONTENTS

What is neoadjuvant chemotherapy?

Why is chemotherapy given before surgery?

Who is eligible?

Which chemotherapy regimens are used?

When is surgery performed?

What are the possible side effects?

The EAU 2026 key message for patients

Multidisciplinary treatment planning with Assoc. Prof. Dr. Serdar Yalçın

Frequently Asked Questions

WHAT IS NEOADJUVANT CHEMOTHERAPY?

Neoadjuvant chemotherapy is drug treatment administered before bladder cancer surgery.

Unlike local treatments, chemotherapy circulates throughout the body, aiming to destroy not only the visible bladder tumor but also microscopic cancer cells that cannot yet be detected by imaging studies.

WHY IS CHEMOTHERAPY GIVEN BEFORE SURGERY?

The objectives are to:

• Eliminate microscopic metastatic disease

• Reduce tumor burden

• Improve the likelihood of complete surgical removal

• Increase long-term survival

• Improve overall oncological outcomes

WHO IS ELIGIBLE?

According to the 2026 European Association of Urology (EAU) Guidelines, neoadjuvant chemotherapy should be considered for patients who have:

• Muscle-Invasive Bladder Cancer (MIBC)

• Adequate kidney function to receive cisplatin-based chemotherapy

• Good overall performance status

• No major contraindications to systemic chemotherapy

Treatment decisions should always be made within a multidisciplinary team.

WHICH CHEMOTHERAPY REGIMENS ARE USED?

Current standard treatment consists of cisplatin-based combination chemotherapy.

The most appropriate regimen depends on kidney function, overall health, performance status, and other individual medical factors.

WHEN IS SURGERY PERFORMED?

After completion of chemotherapy, patients undergo repeat clinical evaluation.

If appropriate, radical cystectomy with pelvic lymph node dissection is then performed without unnecessary delay.

WHAT ARE THE POSSIBLE SIDE EFFECTS?

Potential side effects include:

• Nausea and vomiting

• Fatigue

• Temporary reductions in blood cell counts

• Increased risk of infection

• Kidney function changes in selected patients

Throughout treatment, patients are closely monitored, and supportive care is provided to minimize side effects whenever possible.

THE EAU 2026 KEY MESSAGE FOR PATIENTS

According to the 2026 European Association of Urology (EAU) Guidelines, cisplatin-based neoadjuvant chemotherapy should be offered to eligible patients with Muscle-Invasive Bladder Cancer because it has been shown to improve long-term survival.

Treatment should be carefully coordinated without unnecessary delays.

MULTIDISCIPLINARY TREATMENT PLANNING WITH ASSOC. PROF. DR. SERDAR YALÇIN

Assoc. Prof. Dr. Serdar Yalçın evaluates patients with Muscle-Invasive Bladder Cancer in Bodrum, Türkiye, through a multidisciplinary collaboration involving medical oncology, radiology, pathology, and other relevant specialties.

Each patient’s treatment pathway—including neoadjuvant chemotherapy, robotic radical cystectomy, pelvic lymph node dissection, and urinary diversion—is carefully individualized according to the latest European Association of Urology (EAU) Guidelines.

In addition to patients from Bodrum and the Muğla region, individuals from across Türkiye and abroad seek consultation for second opinions and comprehensive bladder cancer treatment planning.

Patients frequently highlight detailed communication, evidence-based treatment recommendations, multidisciplinary decision-making, individualized care, and continuous support throughout every stage of treatment.

CONCLUSION

Neoadjuvant chemotherapy is an essential component of modern treatment for appropriately selected patients with Muscle-Invasive Bladder Cancer. Careful patient selection, timely chemotherapy, and definitive surgery according to current international guidelines significantly improve long-term oncological outcomes.

FREQUENTLY ASKED QUESTIONS

Will chemotherapy delay my surgery?

No. The goal is to improve cancer outcomes before surgery while maintaining an appropriate treatment timeline.

Can every patient receive neoadjuvant chemotherapy?

No. Eligibility depends primarily on kidney function, overall health, and the ability to tolerate cisplatin-based treatment.

Will I still need surgery after chemotherapy?

In most eligible patients, yes. Radical cystectomy remains a key component of curative treatment.

(Bu içerik Değişik Platformlar taranarak alıntılanmıştır)